Summary
New strategies for cancer therapy must be developed, especially in severe neoplasms such as malignant pleural mesothelioma. Animal models of cancer, as close as possible to the human situation, are needed to investigate novel therapeutical approaches. Orthotopic transplantation of cancer cells is then relevant and efforts should be made to follow up tumour evolution in animals. In the present study, we developed a method for the orthotopic growth of mesothelioma cells in the pleural cavity of Fischer 344 and nude rats, along with a procedure for clinical survey. Two mesothelioma cell lines, of rat and human origin, were inoculated by transthoracic puncture. Body weight determination and chest X-ray analyses permitted the follow-up of tumour evolution by identifying different stages. Autopsies showed that tumours localized on the whole pleural cavity (diaphragm, parietal pleura), mediastinum and pericardium. Tumour morphology and antigenic characteristics were consistent with those of the inoculated cells and were similar in both types of rats inoculated with the same cell type. These results demonstrate that mesothelioma formation in rats can be followed up by clinical and radiographic survey after gentle intrathoracic inoculation of mesothelioma cells, thus allowing the definition of stages of interest for further experimental trials.
Similar content being viewed by others
Article PDF
Change history
16 November 2011
This paper was modified 12 months after initial publication to switch to Creative Commons licence terms, as noted at publication
References
Astoul, P, Viallat, JR, Laurent, JC, Brandely, M & Boutin, C (1993). Intrapleural recombinant IL-2 in passive immunotherapy for malignant pleural effusion. Chest 103: 209–213.
Baselga, J & Mendelsohn, J (1994). The epidermal growth factor receptor as a target for therapy in breast cancer. Breast Cancer Res Treat 29: 127–138.
Bishop, JF (1995). Scheduling of chemotherapy in locally advanced non-small-cell lung cancer. Lung Cancer 12: S53–S61.
Carbone, M, Rizzo, P & Pass, HI (1997). Simian virus 40, poliovaccines and human tumors: a review of recent developments. Oncogene 15: 1877–1888.
Chahinian, AP, Kirschner, PA, Gordon, RE, Szrajer, L & Holland, JF (1991). Usefulness of the nude mouse model in mesothelioma based on a direct patient-xenograft comparison. Cancer 68: 558–560.
Corson, JM (1986). Pathology of malignant mesothelioma. In:Asbestos-Related Malignancy, Antman K Aisner JHarcourt Brace Jovanovich: New York 179–199.
Davis, BM, Koc, ON, Lee, K & Gerson, SL (1996). Current progress in the gene therapy of cancer. Curr Opin Oncol 8: 499–508.
Esandi, MC, van Someren, GD, Vincent, AJPE, van Bekkum, DW, Valerio, D & Bout, A (1997). Gene therapy of experimental malignant mesothelioma using adenovirus vectors encoding the HSVtk gene. Gene Ther 4: 280–287.
Fleury-Feith, J, Nebut, M, Saint-Etienne, L, Laurent, P, Pinchon, MC, Kheuang, L, Renier, A & Jaurand, MC (1989). Occurrence and morphology of tumors induced in nude mice transplanted with chrysotile-transformed rat pleural mesothelial cells. Biol Cell 65: 45–50.
Gutman, M & Fidler, IJ (1995). Biology of cancer colon metastasis. World J Surg 19: 226–234.
Hoogsteden, HC, Langerak, AW, van der Kwast, TH, Versnel, MA & van Gelder, T (1997). Malignant pleural mesothelioma. Crit Rev Oncol Hematol 25: 92–126.
Hwang, HC, Smythe, WR, Elshami, AA, Kucharczuk, JC, Amin, KM, Williams, JP, Litzky, LA, Kaiser, LA & Albelda, SM (1995). Gene therapy using adenovirus carrying the herpes simplex-thymidine kinase gene to treat in vivo models of human malignant mesothelioma and lung cancer. Am J Respir Cell Mol Biol 13: 7–16.
Jaurand, MC, Fleury, J, Monchaux, G, Nebut, M & Bignon, J (1987). Pleural carcinogenic potency of mineral fibers (asbestos, attapulgite) and their cytotoxicity on cultured cells. J Natl Cancer Inst 79: 797–804.
Monchaux, G, Bignon, J, Jaurand, MC, Lafuma, J, Sebastien, P, Masse, R, Hirsch, A & Goni, J (1981). Mesothelioma in rats following inoculation with acid-leached chrysotile asbestos and other mineral fibres. Carcinogenesis 2: 229–236.
Perrin, D, Halazy, S & Hill, B (1997). Inhibitors of ras farnesylation: tomorrow's anticancer agents?. Bull Cancer 84: 635–642.
Ross, G, Erickson, R, Knorr, D, Motulsky, AG, Parkman, R, Samulski, J, Strauss, SE & Smith, BR (1996). Gene therapy in the United States: a five-year status report. Hum Gene Ther 7: 1781–1790.
Smythe, WR, Kaiser, LR, Hwang, HC, Amin, KM, Pilewski, JM, Eck, SJ, Wilson, JM & Albelda, SM (1994). Successful adenovirus-mediated gene transfer in an in vivo model of human malignant mesothelioma. Ann Thorac Surg 57: 1395–1401.
Sterman, DH, Treat, J, Litzky, LA, Amin, KM, Coonrod, L, Molnar-Kimber, K, Recio, A, Knox, L, Wilson, JM, Albelda, SM & Kaiser, LR (1998). Adenovirus-mediated herpes simplex virus thymidine kinase/ganciclovir gene therapy in patients with localized malignancy: results of a phase I clinical trial in malignant mesothelioma. Hum Gene Ther 9: 1083–1092.
Togo, S, Shimada, H, Kubota, T, Moossa, AR & Hoffman, RM (1995). Host organ specifically determines cancer progression. Cancer Res 55: 681–684.
Zeng, L, Fleury-Feith, J, Monnet, I, Boutin, C, Bignon, J & Jaurand, MC (1994). Immunocytochemical characterization of cell lines from human malignant mesothelioma; characterization of human mesothelioma cell lines by immunocytochemistry with a panel of monoclonal antibodies. Hum Pathol 25: 227–234.
Author information
Authors and Affiliations
Rights and permissions
From twelve months after its original publication, this work is licensed under the Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-sa/3.0/
About this article
Cite this article
Pimpec-Barthes, F., Bernard, I., Alsamad, I. et al. Pleuro-pulmonary tumours detected by clinical and chest X-ray analyses in rats transplanted with mesothelioma cells. Br J Cancer 81, 1344–1350 (1999). https://doi.org/10.1038/sj.bjc.6693248
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bjc.6693248